The Prognostic Value of Intermedin in Patients with Breast Cancer
This study aimed to evaluate the prognostic value of preoperative plasma intermedin levels in breast cancer patients. Plasma intermedin levels of 252 breast cancer women and 100 healthy women were determined using radioimmunoassay kit. Adverse event was defined as first local recurrence, distant met...
Gespeichert in:
| Veröffentlicht in: | Disease markers 2015-01, Vol.2015 (2015), p.1-6 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6 |
|---|---|
| container_issue | 2015 |
| container_start_page | 1 |
| container_title | Disease markers |
| container_volume | 2015 |
| creator | Yu, Xiong-Fei Wang, Hai-Yong Zhong, Jian-Bo Lu, Yi-Min Li, Zhong-Qi |
| description | This study aimed to evaluate the prognostic value of preoperative plasma intermedin levels in breast cancer patients. Plasma intermedin levels of 252 breast cancer women and 100 healthy women were determined using radioimmunoassay kit. Adverse event was defined as first local recurrence, distant metastasis, second primary cancer of another organ, or death from any cause during 5-year follow-up. Disease-free survival was defined as the time between surgery and the date of any adverse event whichever appeared first. Overall survival was defined from surgery to death for any cause. The relationships between plasma intermedin levels and clinical outcomes of breast cancer patients were evaluated using multivariate analysis. The results showed that preoperative plasma intermedin levels were substantially higher in patients than in healthy subjects using t-test. Intermedin was identified as an independent predictor for 5-year mortality, adverse event, disease-free survival, and overall survival using multivariate analysis. Based on receiver operating characteristic curve analysis, preoperative plasma intermedin levels had high predictive value for 5-year mortality and adverse event. In conclusion, preoperative plasma intermedin levels are highly associated with poor patient outcomes and intermedin may be a potential prognostic biomarker for patients with breast cancer. |
| doi_str_mv | 10.1155/2015/862158 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4324930</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A454783899</galeid><sourcerecordid>A454783899</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-ee7ac674c1353fe88ebee07f8f7dc0022456a4004dd9477a50b81a0f3645ae023</originalsourceid><addsrcrecordid>eNqN0c1rFDEYBvAgFrtWT95lwIso0775zlwK66K2ULCH6jVkM292I7OZmsxa_O_NMrXUW-GFHPLj4YGHkDcUTimV8owBlWdGMSrNM7KgRsvWKA7PyQKYNi0wAcfkZSk_ASjrRPeCHDOpOqGFXpDlzRab6zxu0lim6JsfbthjM4bmMk2Yd9jH1NS7dlPENJXmLk7b5lNGV6Zm5ZLH_IocBTcUfH3_npDvXz7frC7aq29fL1fLq9YLpacWUTuvtPCUSx7QGFwjgg4m6N4DMCakcgJA9H2tpp2EtaEOAldCOgTGT8j5nHu7X9devtbJbrC3Oe5c_mNHF-3_Pylu7Wb8bQVnouNQA97fB-Tx1x7LZHexeBwGl3DcF0uV1JwayVSl72a6cQPamMJYE_2B26WQQhtuuq6qj7PyeSwlY3goQ8EeprGHaew8TdVvH_d_sP-2qODDDLYx9e4uPi0NK8HgHmFVT_G_WOGeiA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1657318526</pqid></control><display><type>article</type><title>The Prognostic Value of Intermedin in Patients with Breast Cancer</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Yu, Xiong-Fei ; Wang, Hai-Yong ; Zhong, Jian-Bo ; Lu, Yi-Min ; Li, Zhong-Qi</creator><contributor>Rebelo, Irene</contributor><creatorcontrib>Yu, Xiong-Fei ; Wang, Hai-Yong ; Zhong, Jian-Bo ; Lu, Yi-Min ; Li, Zhong-Qi ; Rebelo, Irene</creatorcontrib><description>This study aimed to evaluate the prognostic value of preoperative plasma intermedin levels in breast cancer patients. Plasma intermedin levels of 252 breast cancer women and 100 healthy women were determined using radioimmunoassay kit. Adverse event was defined as first local recurrence, distant metastasis, second primary cancer of another organ, or death from any cause during 5-year follow-up. Disease-free survival was defined as the time between surgery and the date of any adverse event whichever appeared first. Overall survival was defined from surgery to death for any cause. The relationships between plasma intermedin levels and clinical outcomes of breast cancer patients were evaluated using multivariate analysis. The results showed that preoperative plasma intermedin levels were substantially higher in patients than in healthy subjects using t-test. Intermedin was identified as an independent predictor for 5-year mortality, adverse event, disease-free survival, and overall survival using multivariate analysis. Based on receiver operating characteristic curve analysis, preoperative plasma intermedin levels had high predictive value for 5-year mortality and adverse event. In conclusion, preoperative plasma intermedin levels are highly associated with poor patient outcomes and intermedin may be a potential prognostic biomarker for patients with breast cancer.</description><identifier>ISSN: 0278-0240</identifier><identifier>EISSN: 1875-8630</identifier><identifier>DOI: 10.1155/2015/862158</identifier><identifier>PMID: 25694747</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Adult ; Biomarkers, Tumor - blood ; Blood plasma ; Breast cancer ; Breast Neoplasms - blood ; Breast Neoplasms - pathology ; Care and treatment ; Composition ; Development and progression ; Disease-Free Survival ; Female ; Health aspects ; Humans ; Intermedin ; Middle Aged ; Peptide Hormones - blood ; Predictive Value of Tests</subject><ispartof>Disease markers, 2015-01, Vol.2015 (2015), p.1-6</ispartof><rights>Copyright © 2015 Yi-Min Lu et al.</rights><rights>COPYRIGHT 2015 John Wiley & Sons, Inc.</rights><rights>Copyright © 2015 Yi-Min Lu et al. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-ee7ac674c1353fe88ebee07f8f7dc0022456a4004dd9477a50b81a0f3645ae023</citedby><cites>FETCH-LOGICAL-c467t-ee7ac674c1353fe88ebee07f8f7dc0022456a4004dd9477a50b81a0f3645ae023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324930/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324930/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25694747$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Rebelo, Irene</contributor><creatorcontrib>Yu, Xiong-Fei</creatorcontrib><creatorcontrib>Wang, Hai-Yong</creatorcontrib><creatorcontrib>Zhong, Jian-Bo</creatorcontrib><creatorcontrib>Lu, Yi-Min</creatorcontrib><creatorcontrib>Li, Zhong-Qi</creatorcontrib><title>The Prognostic Value of Intermedin in Patients with Breast Cancer</title><title>Disease markers</title><addtitle>Dis Markers</addtitle><description>This study aimed to evaluate the prognostic value of preoperative plasma intermedin levels in breast cancer patients. Plasma intermedin levels of 252 breast cancer women and 100 healthy women were determined using radioimmunoassay kit. Adverse event was defined as first local recurrence, distant metastasis, second primary cancer of another organ, or death from any cause during 5-year follow-up. Disease-free survival was defined as the time between surgery and the date of any adverse event whichever appeared first. Overall survival was defined from surgery to death for any cause. The relationships between plasma intermedin levels and clinical outcomes of breast cancer patients were evaluated using multivariate analysis. The results showed that preoperative plasma intermedin levels were substantially higher in patients than in healthy subjects using t-test. Intermedin was identified as an independent predictor for 5-year mortality, adverse event, disease-free survival, and overall survival using multivariate analysis. Based on receiver operating characteristic curve analysis, preoperative plasma intermedin levels had high predictive value for 5-year mortality and adverse event. In conclusion, preoperative plasma intermedin levels are highly associated with poor patient outcomes and intermedin may be a potential prognostic biomarker for patients with breast cancer.</description><subject>Adult</subject><subject>Biomarkers, Tumor - blood</subject><subject>Blood plasma</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - pathology</subject><subject>Care and treatment</subject><subject>Composition</subject><subject>Development and progression</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Intermedin</subject><subject>Middle Aged</subject><subject>Peptide Hormones - blood</subject><subject>Predictive Value of Tests</subject><issn>0278-0240</issn><issn>1875-8630</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><recordid>eNqN0c1rFDEYBvAgFrtWT95lwIso0775zlwK66K2ULCH6jVkM292I7OZmsxa_O_NMrXUW-GFHPLj4YGHkDcUTimV8owBlWdGMSrNM7KgRsvWKA7PyQKYNi0wAcfkZSk_ASjrRPeCHDOpOqGFXpDlzRab6zxu0lim6JsfbthjM4bmMk2Yd9jH1NS7dlPENJXmLk7b5lNGV6Zm5ZLH_IocBTcUfH3_npDvXz7frC7aq29fL1fLq9YLpacWUTuvtPCUSx7QGFwjgg4m6N4DMCakcgJA9H2tpp2EtaEOAldCOgTGT8j5nHu7X9devtbJbrC3Oe5c_mNHF-3_Pylu7Wb8bQVnouNQA97fB-Tx1x7LZHexeBwGl3DcF0uV1JwayVSl72a6cQPamMJYE_2B26WQQhtuuq6qj7PyeSwlY3goQ8EeprGHaew8TdVvH_d_sP-2qODDDLYx9e4uPi0NK8HgHmFVT_G_WOGeiA</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Yu, Xiong-Fei</creator><creator>Wang, Hai-Yong</creator><creator>Zhong, Jian-Bo</creator><creator>Lu, Yi-Min</creator><creator>Li, Zhong-Qi</creator><general>Hindawi Publishing Corporation</general><general>John Wiley & Sons, Inc</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>The Prognostic Value of Intermedin in Patients with Breast Cancer</title><author>Yu, Xiong-Fei ; Wang, Hai-Yong ; Zhong, Jian-Bo ; Lu, Yi-Min ; Li, Zhong-Qi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-ee7ac674c1353fe88ebee07f8f7dc0022456a4004dd9477a50b81a0f3645ae023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Biomarkers, Tumor - blood</topic><topic>Blood plasma</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - pathology</topic><topic>Care and treatment</topic><topic>Composition</topic><topic>Development and progression</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Intermedin</topic><topic>Middle Aged</topic><topic>Peptide Hormones - blood</topic><topic>Predictive Value of Tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yu, Xiong-Fei</creatorcontrib><creatorcontrib>Wang, Hai-Yong</creatorcontrib><creatorcontrib>Zhong, Jian-Bo</creatorcontrib><creatorcontrib>Lu, Yi-Min</creatorcontrib><creatorcontrib>Li, Zhong-Qi</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Disease markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yu, Xiong-Fei</au><au>Wang, Hai-Yong</au><au>Zhong, Jian-Bo</au><au>Lu, Yi-Min</au><au>Li, Zhong-Qi</au><au>Rebelo, Irene</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Prognostic Value of Intermedin in Patients with Breast Cancer</atitle><jtitle>Disease markers</jtitle><addtitle>Dis Markers</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>2015</volume><issue>2015</issue><spage>1</spage><epage>6</epage><pages>1-6</pages><issn>0278-0240</issn><eissn>1875-8630</eissn><abstract>This study aimed to evaluate the prognostic value of preoperative plasma intermedin levels in breast cancer patients. Plasma intermedin levels of 252 breast cancer women and 100 healthy women were determined using radioimmunoassay kit. Adverse event was defined as first local recurrence, distant metastasis, second primary cancer of another organ, or death from any cause during 5-year follow-up. Disease-free survival was defined as the time between surgery and the date of any adverse event whichever appeared first. Overall survival was defined from surgery to death for any cause. The relationships between plasma intermedin levels and clinical outcomes of breast cancer patients were evaluated using multivariate analysis. The results showed that preoperative plasma intermedin levels were substantially higher in patients than in healthy subjects using t-test. Intermedin was identified as an independent predictor for 5-year mortality, adverse event, disease-free survival, and overall survival using multivariate analysis. Based on receiver operating characteristic curve analysis, preoperative plasma intermedin levels had high predictive value for 5-year mortality and adverse event. In conclusion, preoperative plasma intermedin levels are highly associated with poor patient outcomes and intermedin may be a potential prognostic biomarker for patients with breast cancer.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>25694747</pmid><doi>10.1155/2015/862158</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0240 |
| ispartof | Disease markers, 2015-01, Vol.2015 (2015), p.1-6 |
| issn | 0278-0240 1875-8630 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4324930 |
| source | MEDLINE; Wiley Online Library Open Access; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adult Biomarkers, Tumor - blood Blood plasma Breast cancer Breast Neoplasms - blood Breast Neoplasms - pathology Care and treatment Composition Development and progression Disease-Free Survival Female Health aspects Humans Intermedin Middle Aged Peptide Hormones - blood Predictive Value of Tests |
| title | The Prognostic Value of Intermedin in Patients with Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T06%3A48%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Prognostic%20Value%20of%20Intermedin%20in%20Patients%20with%20Breast%20Cancer&rft.jtitle=Disease%20markers&rft.au=Yu,%20Xiong-Fei&rft.date=2015-01-01&rft.volume=2015&rft.issue=2015&rft.spage=1&rft.epage=6&rft.pages=1-6&rft.issn=0278-0240&rft.eissn=1875-8630&rft_id=info:doi/10.1155/2015/862158&rft_dat=%3Cgale_pubme%3EA454783899%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1657318526&rft_id=info:pmid/25694747&rft_galeid=A454783899&rfr_iscdi=true |